WebDec 12, 2024 · Dr Ekaterina Malievskaia, Chief Innovation Officer and Co-Founder, COMPASS Pathways, said, "This study is part of our overall clinical development programme in treatment-resistant depression; we ... WebNov 28, 2024 · Compass Pathways (CMPS-2.71%) has released data for a phase 2b study of its COMP360 psilocybin treatment for depression. In this Motley Fool Live video recorded on November 15, Motley Fool ...
COMPASS Pathways to participate in upcoming 22nd Annual …
WebDec 8, 2024 · COMPASS Pathways launches phase 2 clinical trial of psilocybin therapy in anorexia nervosa. Multi-centre, double-blind randomised controlled phase 2 trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological treatment option. ... This press release … WebNov 3, 2024 · COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of … hospitality room clip art
News release - COMPASS Pathways plc
WebNov 9, 2024 · Full Press Release from COMPASS Pathways. COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression. Largest randomised, controlled, double-blind psilocybin therapy study ever completed shows rapid and … WebNov 3, 2024 · Cash position at 30 September 2024 of $173.1 million. Conference call today at 8:00am ET (12:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), … WebJul 6, 2024 · Compass Pathways, in which he owns a 7 ... Among Compass’ critics is the quirky soap company Dr. Bronner’s, which went after the company’s April filing in a press release: ... hospitality rota